Figure 9. mAb04-MICA demonstrated in vivo efficacy against a MDA-MB-231 xenograft.

A, B. Tumor growth curves for nude mice. Each BALB/c nude mouse was subcutaneously injected 1×10⁷ MDA-MB-231 cells for different treatment. Treatment began following tumor development, and the measurement of tumor volume started as well. C, D. Tumor inhibition rates of different dosage groups. mAb04-MICA significantly improved tumor inhibition rate compared to mAb04/Docetaxel. Data were presented as the mean ± SD, *p < 0.05, **p < 0.01. E, F. Survival curves for nude mice bearing tumor. mAb04-MICA had noteworthy survival benefit compared to mAb04 + Docetaxel or Avastin + Docetaxel.